Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oxford Health Plan (OXHP) -- Ignore unavailable to you. Want to Upgrade?

To: Michael Harb who wrote (1006)	2/10/1998 9:32:00 AM
From: Worswick	Read Replies (3) \| Respond to of 2068

Trash time is over here traders. The stock will sell down on the news and then on the earnings announcement. Then, upwards.... Public Radio this morning says that KKR, or another group that pulled Continental back from the brink is putting in a $200 million equity investment in OXHP. With Michael Price and Henry Kravis in this stock Kravis can't do an LBO and take out the weenies (us). This is a value stock with a great franchise. Wiggins is being sent to that land reserved for visionaries who don't have day to day company responsibilities anymore. Rolling out a few years ahead, this is a franchise that can be fixed. You can bet that KKR and Price went over the books and whatever the warts are that.... was also the opportunity. Got it? All you negative people who have trashed and thrashed this stock for the last three months in hundreds and hundreds of posts, everyone of which I read, game over. How many of us hung in here - Thomas and others - in the last months when it got really rough? Whew. Between times the latest S&P report. For Private Use Only (C) S&P "....we maintain an accumulate opinion on this beaten-down stock, as the prospect for a resumption of earnings momentum lies in the company's strong commercial business, where both enrollment and cost trends remain positive. We look for a fourth quarter operating loss in the $2.00 range, as N.Y. State Insurance regulators have forced the company to boost its medical reserves by about $164 million in order to protect policyholders from possible solvency issues. While the stock may struggle in coming months, we feel that a sharper focus on the commercial segment will allow for 1998 EPS of about $1.40, assuming management can lower both medical and administrative costs while generating enrollment growth of about 20%. Oxford has also become a logical takeover play, and we feel OXHP would command at least $35 per share in a deal, or roughly $1,400 per member."